Get 25% off an annual STAT+ subscription and read more of our award-winning journalism. www.statnews.com Join the STAT+ community today to get access to last month's top stories and much more. Subscribe now for 25% off your first year. MOLLY FERGUSON/STAT A conflict of interest behind the warning on Apellis' eye drug? The optics are not good by Adam Feuerstein READ MORE EROS DERVISHI FOR STAT How UnitedHealth's acquisition of a popular Medicare Advantage algorithm sparked internal dissent over denied care by Casey Ross and Bob Herman READ MORE MOLLY FERGUSON FOR STAT With savvy bets, a dynamic duo makes Eli Lilly one of pharma's biggest success stories by Matthew Herper READ MORE MORE TOP STORIES The new weight loss drugs are revolutionizing our understanding of desire. Food cravings could be just the beginning by Megan Molteni Novo Nordisk bought prescribers over 450,000 meals and snacks to promote drugs like Ozempic by Nicholas FlorkoFDA approves first Alzheimer's therapy shown to clearly slow cognitive decline by Adam Feuerstein and Damian GardeThe biotech scorecard for the third quarter: 15 stock-moving events to watch by Adam FeuersteinIQVIA has grown unchecked into a health data juggernaut. Will the FTC rein it in? by Casey RossAs Alzheimer's drugs hit the market, the race for early detection blood tests heats up by Brittany TrangBlue Cross Blue Shield plans in California evaded $170 million in taxes, whistleblower says by Bob Herman SUBSCRIBE Wednesday, August 2, 2023 1 Exchange Place, Boston, MA 02109 ©2023, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us
No comments